Mabpharm Limited Updates Nomination Committee Terms
I'm PortAI, I can summarize articles.
Mabpharm Limited (HK:2181) has updated the terms of reference for its Nomination Committee, which will now review the board’s structure, assess director independence, support performance evaluations, and oversee succession planning. The latest analyst rating for Mabpharm's stock is a Hold with a price target of HK$0.50. The company, incorporated in the Cayman Islands, has a market cap of HK$2.35B and an average trading volume of 701,064 shares.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments